Request a Meeting
contact mi

The Zephyr® Endobronchial Valve is clinically proven to improve lung function, exercise capacity, dyspnea, and quality of life for patients with emphysema. Our patient selection tools — StratX® Lung Analysis Platform and Chartis® Pulmonary Assessment System — enable physicians to successfully predict outcomes and provide optimal treatment for each individual patient. The Zephyr Valve is the first endobronchial valve to receive approval from the FDA for patients with either heterogeneous or homogeneous emphysema and can be used to treat the upper and lower lobes of either lung. More than 20,000 patients globally have received Zephyr Valves.

Visit: Pulmonx.com


product resources
video library